Zions Bancorporation’s Oncolytics Biotech ONCY Stock Holding History

Zions Bancorporation’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,000	Closed	-$8K	–	1130
2022 Q1	$8K	Hold	5,000	–	–	﹤0.01%	866
2021 Q4	$7K	Hold	5,000	–	–	﹤0.01%	806
2021 Q3	$10K	Hold	5,000	–	–	﹤0.01%	732
2021 Q2	$14K	Hold	5,000	–	–	﹤0.01%	660
2021 Q1	$19K	Buy	+5,000	New	+$14.9K	﹤0.01%	580

Other funds holding ONCY

ARC

Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Zions Bancorporation's ONCY Position: Q2 2022 in Review

Zions Bancorporation sold out of Oncolytics Biotech (ONCY) in Q2 2022, closing a stake of 5,000 shares — an estimated $8K sold.

Zions Bancorporation first reported a position in ONCY in Q1 2021 and held it in 5 quarters. The position peaked at $19K in Q1 2021. 42 funds tracked by Wall St. Rank hold ONCY as of Q2 2022.

Zions Bancorporation reported no remaining Oncolytics Biotech position as of Q2 2022 after selling out during the quarter.
Zions Bancorporation sold 5,000 Oncolytics Biotech shares in Q2 2022, an estimated $8K.
Zions Bancorporation first reported a position in Oncolytics Biotech in Q1 2021 and held it in 5 quarters.
Zions Bancorporation's Oncolytics Biotech position peaked at $19K in Q1 2021.
42 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2022.

Based on Zions Bancorporation's 13F filing for Q2 2022, filed 5 Aug 2022.